 Vijaya Vemulakonda
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Obstruction | 7 | 2024 | 59 | 4.200 |
Why?
| | Urologic Surgical Procedures | 16 | 2024 | 107 | 4.070 |
Why?
| | Hydronephrosis | 7 | 2024 | 34 | 2.910 |
Why?
| | Urology | 8 | 2024 | 57 | 2.410 |
Why?
| | Kidney Pelvis | 4 | 2024 | 24 | 1.880 |
Why?
| | Urinary Bladder | 6 | 2022 | 175 | 1.670 |
Why?
| | Electronic Health Records | 6 | 2022 | 973 | 1.640 |
Why?
| | Vesico-Ureteral Reflux | 4 | 2024 | 26 | 1.530 |
Why?
| | Fetal Diseases | 2 | 2022 | 156 | 1.460 |
Why?
| | Renal Insufficiency | 2 | 2023 | 148 | 1.420 |
Why?
| | Kidney | 6 | 2024 | 1306 | 1.250 |
Why?
| | Infant | 26 | 2025 | 8912 | 1.170 |
Why?
| | Urinary Tract Infections | 5 | 2025 | 144 | 1.160 |
Why?
| | Pediatrics | 4 | 2019 | 1044 | 1.040 |
Why?
| | Urethral Diseases | 3 | 2022 | 19 | 0.990 |
Why?
| | Urinary Tract | 2 | 2024 | 38 | 0.980 |
Why?
| | Decision Making | 3 | 2024 | 846 | 0.920 |
Why?
| | Practice Patterns, Physicians' | 5 | 2025 | 1260 | 0.890 |
Why?
| | Urogenital Abnormalities | 3 | 2025 | 52 | 0.860 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 118 | 0.860 |
Why?
| | Child | 36 | 2025 | 20636 | 0.840 |
Why?
| | Urologists | 2 | 2020 | 17 | 0.800 |
Why?
| | Urethral Obstruction | 1 | 2022 | 9 | 0.790 |
Why?
| | Amniotic Fluid | 1 | 2022 | 86 | 0.780 |
Why?
| | Urologic Diseases | 3 | 2018 | 38 | 0.730 |
Why?
| | Multicystic Dysplastic Kidney | 1 | 2020 | 3 | 0.720 |
Why?
| | Kidney Diseases, Cystic | 1 | 2020 | 20 | 0.710 |
Why?
| | Kidney Transplantation | 2 | 2022 | 603 | 0.700 |
Why?
| | Hypospadias | 2 | 2018 | 28 | 0.690 |
Why?
| | Urinary Bladder, Neurogenic | 5 | 2022 | 35 | 0.690 |
Why?
| | Ultrasonography, Prenatal | 5 | 2022 | 270 | 0.690 |
Why?
| | Documentation | 1 | 2022 | 181 | 0.680 |
Why?
| | Biomedical Research | 2 | 2018 | 632 | 0.680 |
Why?
| | Child, Preschool | 21 | 2025 | 10378 | 0.660 |
Why?
| | Humans | 59 | 2025 | 128019 | 0.640 |
Why?
| | Qualitative Research | 5 | 2022 | 1224 | 0.630 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 15 | 0.610 |
Why?
| | Fasting | 1 | 2020 | 264 | 0.610 |
Why?
| | Stakeholder Participation | 1 | 2019 | 77 | 0.600 |
Why?
| | Urinary Incontinence | 2 | 2016 | 61 | 0.590 |
Why?
| | Parents | 3 | 2023 | 1303 | 0.580 |
Why?
| | Preoperative Care | 1 | 2020 | 335 | 0.580 |
Why?
| | Postnatal Care | 2 | 2015 | 71 | 0.580 |
Why?
| | Urinary Fistula | 1 | 2017 | 9 | 0.560 |
Why?
| | Prenatal Diagnosis | 2 | 2020 | 190 | 0.540 |
Why?
| | Outpatients | 1 | 2020 | 366 | 0.540 |
Why?
| | Anesthesia | 1 | 2018 | 129 | 0.530 |
Why?
| | Epispadias | 1 | 2016 | 4 | 0.530 |
Why?
| | Bladder Exstrophy | 1 | 2016 | 16 | 0.530 |
Why?
| | Urogenital Surgical Procedures | 1 | 2016 | 5 | 0.530 |
Why?
| | Retrospective Studies | 22 | 2025 | 14404 | 0.520 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 302 | 0.520 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.520 |
Why?
| | Intermittent Urethral Catheterization | 1 | 2016 | 3 | 0.520 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 540 | 0.520 |
Why?
| | Female | 36 | 2025 | 68016 | 0.510 |
Why?
| | Spinal Dysraphism | 2 | 2017 | 59 | 0.500 |
Why?
| | Risk Assessment | 5 | 2024 | 3223 | 0.490 |
Why?
| | Appointments and Schedules | 2 | 2014 | 81 | 0.490 |
Why?
| | Cultural Diversity | 2 | 2022 | 62 | 0.470 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2008 | 226 | 0.470 |
Why?
| | Infant, Newborn | 10 | 2025 | 5688 | 0.460 |
Why?
| | Hernia, Umbilical | 1 | 2014 | 16 | 0.440 |
Why?
| | Anus, Imperforate | 1 | 2014 | 24 | 0.440 |
Why?
| | Internship and Residency | 4 | 2024 | 1043 | 0.430 |
Why?
| | Urethra | 1 | 2014 | 52 | 0.430 |
Why?
| | Male | 33 | 2025 | 62757 | 0.420 |
Why?
| | Tumor Burden | 1 | 2013 | 283 | 0.400 |
Why?
| | Wilms Tumor | 1 | 2013 | 77 | 0.400 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2012 | 55 | 0.390 |
Why?
| | Referral and Consultation | 1 | 2017 | 724 | 0.380 |
Why?
| | Patient Selection | 1 | 2015 | 658 | 0.380 |
Why?
| | Botulinum Toxins, Type A | 3 | 2011 | 39 | 0.370 |
Why?
| | Physicians | 1 | 2020 | 858 | 0.370 |
Why?
| | Scoliosis | 1 | 2014 | 201 | 0.360 |
Why?
| | Data Collection | 1 | 2014 | 645 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1356 | 0.330 |
Why?
| | Postoperative Complications | 5 | 2024 | 2456 | 0.320 |
Why?
| | Ultrasonography | 3 | 2021 | 708 | 0.320 |
Why?
| | Tertiary Care Centers | 3 | 2019 | 146 | 0.310 |
Why?
| | Pregnancy | 4 | 2022 | 6355 | 0.310 |
Why?
| | Adolescent | 15 | 2025 | 20158 | 0.310 |
Why?
| | Dextrans | 1 | 2009 | 82 | 0.310 |
Why?
| | Cystitis | 2 | 2005 | 22 | 0.300 |
Why?
| | Prospective Studies | 5 | 2024 | 7035 | 0.300 |
Why?
| | Prune Belly Syndrome | 1 | 2007 | 7 | 0.290 |
Why?
| | Ethics, Professional | 1 | 2007 | 15 | 0.280 |
Why?
| | Follow-Up Studies | 6 | 2019 | 4853 | 0.280 |
Why?
| | Hyaluronic Acid | 1 | 2009 | 211 | 0.280 |
Why?
| | Diurnal Enuresis | 1 | 2006 | 1 | 0.270 |
Why?
| | Stomach Neoplasms | 1 | 2008 | 97 | 0.270 |
Why?
| | Competency-Based Education | 1 | 2007 | 68 | 0.260 |
Why?
| | Education, Medical, Graduate | 2 | 2024 | 433 | 0.260 |
Why?
| | Professional Competence | 1 | 2007 | 94 | 0.260 |
Why?
| | Adenoma | 1 | 2007 | 212 | 0.250 |
Why?
| | Databases, Factual | 3 | 2022 | 1264 | 0.240 |
Why?
| | Biocompatible Materials | 1 | 2009 | 396 | 0.240 |
Why?
| | Incidence | 4 | 2024 | 2614 | 0.240 |
Why?
| | Feasibility Studies | 2 | 2022 | 860 | 0.230 |
Why?
| | Neuromuscular Agents | 1 | 2005 | 30 | 0.230 |
Why?
| | Renal Artery | 1 | 2024 | 33 | 0.220 |
Why?
| | Dissent and Disputes | 1 | 2023 | 17 | 0.220 |
Why?
| | Muscle, Smooth | 2 | 2022 | 152 | 0.210 |
Why?
| | United States | 9 | 2025 | 13785 | 0.200 |
Why?
| | Propensity Score | 1 | 2024 | 264 | 0.200 |
Why?
| | Urinary Bladder Diseases | 1 | 2022 | 18 | 0.200 |
Why?
| | Vascular Resistance | 1 | 2024 | 366 | 0.200 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3009 | 0.200 |
Why?
| | Pain, Postoperative | 1 | 2024 | 222 | 0.200 |
Why?
| | Drug Prescriptions | 1 | 2024 | 245 | 0.200 |
Why?
| | Duodenum | 1 | 2022 | 71 | 0.200 |
Why?
| | Patient Care | 1 | 2023 | 108 | 0.200 |
Why?
| | Laparoscopy | 2 | 2022 | 450 | 0.200 |
Why?
| | Sexual Development | 1 | 2022 | 19 | 0.200 |
Why?
| | Registries | 2 | 2022 | 1873 | 0.190 |
Why?
| | Postoperative Period | 2 | 2020 | 322 | 0.190 |
Why?
| | Ureter | 1 | 2022 | 35 | 0.190 |
Why?
| | Probability | 1 | 2022 | 304 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 955 | 0.190 |
Why?
| | Social Justice | 1 | 2022 | 77 | 0.190 |
Why?
| | Bacteremia | 1 | 2024 | 192 | 0.190 |
Why?
| | Urination | 3 | 2014 | 44 | 0.190 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 87 | 0.190 |
Why?
| | Injury Severity Score | 1 | 2023 | 509 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 332 | 0.180 |
Why?
| | Urography | 2 | 2014 | 15 | 0.180 |
Why?
| | Hospitals, Pediatric | 2 | 2025 | 505 | 0.180 |
Why?
| | Clinical Competence | 1 | 2008 | 1007 | 0.180 |
Why?
| | Trauma Centers | 1 | 2023 | 400 | 0.180 |
Why?
| | Adenocarcinoma | 1 | 2008 | 888 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2022 | 226 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2023 | 271 | 0.170 |
Why?
| | Actins | 1 | 2022 | 401 | 0.170 |
Why?
| | Cohort Studies | 4 | 2024 | 5378 | 0.170 |
Why?
| | Anti-Bacterial Agents | 3 | 2025 | 1689 | 0.170 |
Why?
| | General Surgery | 2 | 2024 | 152 | 0.160 |
Why?
| | Ambulatory Care | 2 | 2022 | 500 | 0.160 |
Why?
| | Patient Portals | 1 | 2019 | 42 | 0.160 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 562 | 0.150 |
Why?
| | User-Computer Interface | 1 | 2019 | 147 | 0.150 |
Why?
| | Bacteriuria | 1 | 2018 | 7 | 0.150 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2018 | 29 | 0.150 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5353 | 0.150 |
Why?
| | Disorders of Sex Development | 1 | 2018 | 39 | 0.150 |
Why?
| | Renal Dialysis | 1 | 2022 | 420 | 0.140 |
Why?
| | Curriculum | 1 | 2024 | 909 | 0.140 |
Why?
| | Social Support | 1 | 2022 | 588 | 0.140 |
Why?
| | Cystostomy | 1 | 2017 | 9 | 0.140 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 886 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2021 | 10110 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 777 | 0.130 |
Why?
| | Analgesia | 1 | 2017 | 92 | 0.130 |
Why?
| | Perioperative Care | 1 | 2018 | 149 | 0.130 |
Why?
| | Genital Diseases, Male | 1 | 2016 | 17 | 0.130 |
Why?
| | Fetus | 1 | 2020 | 760 | 0.130 |
Why?
| | Adult | 8 | 2024 | 35176 | 0.130 |
Why?
| | Reoperation | 1 | 2018 | 541 | 0.120 |
Why?
| | Global Health | 1 | 2018 | 327 | 0.120 |
Why?
| | Caregivers | 1 | 2022 | 810 | 0.120 |
Why?
| | Length of Stay | 3 | 2025 | 1114 | 0.120 |
Why?
| | Risk Factors | 5 | 2018 | 9696 | 0.120 |
Why?
| | Health Information Exchange | 1 | 2014 | 18 | 0.110 |
Why?
| | Recovery of Function | 1 | 2018 | 630 | 0.110 |
Why?
| | ROC Curve | 1 | 2015 | 500 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 3100 | 0.110 |
Why?
| | Cloaca | 1 | 2014 | 48 | 0.110 |
Why?
| | Program Evaluation | 2 | 2008 | 872 | 0.110 |
Why?
| | Cystoscopy | 2 | 2011 | 18 | 0.090 |
Why?
| | Urinary Retention | 1 | 2011 | 20 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 329 | 0.090 |
Why?
| | Sex Factors | 3 | 2018 | 1942 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2703 | 0.080 |
Why?
| | Patient Compliance | 1 | 2014 | 558 | 0.080 |
Why?
| | Ureteroscopy | 1 | 2009 | 16 | 0.080 |
Why?
| | Injections | 1 | 2009 | 172 | 0.080 |
Why?
| | Electrocoagulation | 1 | 2007 | 38 | 0.070 |
Why?
| | Stomach | 1 | 2008 | 109 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 149 | 0.070 |
Why?
| | Medical Staff, Hospital | 1 | 2007 | 77 | 0.070 |
Why?
| | Educational Measurement | 1 | 2008 | 257 | 0.060 |
Why?
| | Professional Role | 1 | 2007 | 156 | 0.060 |
Why?
| | Urothelium | 1 | 2005 | 37 | 0.060 |
Why?
| | Administration, Intravesical | 1 | 2005 | 15 | 0.060 |
Why?
| | Program Development | 1 | 2007 | 357 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 263 | 0.060 |
Why?
| | Colorado | 1 | 2014 | 4369 | 0.060 |
Why?
| | Biopsy | 1 | 2007 | 1077 | 0.060 |
Why?
| | Phimosis | 1 | 2003 | 1 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2509 | 0.050 |
Why?
| | Circumcision, Male | 1 | 2003 | 13 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 3874 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2005 | 469 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2258 | 0.050 |
Why?
| | Treatment Failure | 1 | 2024 | 338 | 0.050 |
Why?
| | Disease Management | 1 | 2006 | 583 | 0.050 |
Why?
| | Career Choice | 1 | 2024 | 207 | 0.050 |
Why?
| | Chronic Disease | 2 | 2005 | 1690 | 0.050 |
Why?
| | Abortion, Induced | 1 | 2024 | 101 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3371 | 0.050 |
Why?
| | Advisory Committees | 1 | 2022 | 214 | 0.040 |
Why?
| | Rats | 2 | 2005 | 5199 | 0.040 |
Why?
| | Cryptorchidism | 1 | 2018 | 14 | 0.040 |
Why?
| | Urolithiasis | 1 | 2018 | 9 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2018 | 53 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 114 | 0.040 |
Why?
| | Urine | 1 | 2018 | 56 | 0.040 |
Why?
| | Stents | 1 | 2022 | 504 | 0.040 |
Why?
| | Constipation | 1 | 2018 | 88 | 0.030 |
Why?
| | Young Adult | 2 | 2022 | 12281 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2057 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1492 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 1896 | 0.030 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 108 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1975 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 1093 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2011 | 34 | 0.020 |
Why?
| | Urodynamics | 1 | 2011 | 35 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3324 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2672 | 0.020 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2011 | 54 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3766 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2011 | 236 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1012 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1199 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2011 | 292 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6479 | 0.020 |
Why?
| | Animals | 2 | 2005 | 34487 | 0.020 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2005 | 9 | 0.020 |
Why?
| | Mechanoreceptors | 1 | 2005 | 14 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2005 | 33 | 0.020 |
Why?
| | Physical Stimulation | 1 | 2005 | 74 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2005 | 227 | 0.010 |
Why?
| | Sensory Receptor Cells | 1 | 2005 | 93 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2005 | 423 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2005 | 3936 | 0.010 |
Why?
|
|
Vemulakonda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|